Daniel Peter Petrylak MD

Genitourinary Oncology, Hematologic Oncology

Yale University Cancer Center

35 Park Street Np4New Haven, CT 06510
Phone+1 203-200-4822
Fax+1 203-785-4043

Dr. Petrylak is on Doximity

As a Doximity member, you’ll join more than three million U.S. healthcare professionals—including 85+% of physicians, and 2/3 of all NPs and PAs—in a private, secure network.

Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
Connect with colleagues in the same hospital or clinic.
Read the latest clinical news, personalized to your specialty.

See Dr. Petrylak's full profile Already have an account?

Summary

Daniel Petrylak, MD, is an experienced Oncologist located in New Haven, CT, who holds subspecialties in Genitourinary Oncology and Hematologic Oncology. He especially excels in the areas of neuro-oncology, renal cell carcinoma, prostate cancer, gynecologic oncology, and urologic oncology. He served as a Professor of Medicine at NewYork-Presbyterian/Columbia University Irving Medical Center for over two decades. A seasoned researcher, Dr. Petrylak also ran numerous clinical trials and had several publications under his name, particularly focusing on advanced urothelial and prostate cancer. Earlier in his career, he completed a fellowship at the Memorial Sloan Kettering Cancer Center and a residency at the Jacobi Medical Center/Albert Einstein College of Medicine. His notable recognitions include numerous listings among America's Top Doctors and Top Doctors in the New York Metro Area from Castle Connolly.

Education & Training

Memorial Sloan Kettering Cancer CenterFellowship, Hematology and Medical Oncology, 1988 - 1991
Jacobi Medical Center/Albert Einstein College of MedicineResidency, Internal Medicine, 1985 - 1988
Case Western Reserve University School of MedicineClass of 1985

The following disclaimer is related to board certifications obtained from ABMS®, denoted by the ABMS® logo.

This information is proprietary data maintained in a copyrighted database owned by the American Board of Medical Specialties®. The display and presence of ABMS Data in no way constitutes any affiliation, association with, or endorsement of any advertising, promotion, or sponsorship by ABMS and its affiliates and subsidiaries, the ABMS Member Boards, or ABMS board certified physicians and medical specialists. Copyright 2026 American Board of Medical Specialties®. All rights reserved.

The user is responsible for ensuring that the profile obtained in this directory is the profile of the physician or medical specialist being sought.

A self-designated specialty, subspecialty, or practice area neither implies nor is equivalent to ABMS board certification or the existence of specialized training by or competence of a physician or medical specialist.

Certifications & Licensure

NY State Medical License 1985 - 2028
CT State Medical License 2012 - 2027
American Board of Internal Medicine Medical Oncology

Awards, Honors, & Recognition

CMS Meaningful Use Stage 1 Certification EpicCare Ambulatory 2014 Certified EHR Suite, Epic Systems Corporation, 2014, 2016-2017
CMS Meaningful Use Stage 2 Certification EpicCare Ambulatory 2014 Certified EHR Suite, Epic Systems Corporation, 2014, 2016-2017
CMS Meaningful Use Stage 1 Certification EpicCare Ambulatory EMR, Epic Systems Corporation, 2014

Clinical Trials

Low, Intermediate, or High Dose Suramin in Treating Patients With Hormone-Refractory Prostate Cancer
COMPLETED
PHASE3
Docetaxel Plus Estramustine in Treating Patients With Metastatic Prostate Cancer
UNKNOWN
PHASE1, PHASE2
Combination Chemotherapy in Treating Patients With Advanced Prostate Cancer
UNKNOWN
PHASE1

Publications & Presentations

PubMed

1 citations
20 years of taxane therapy in prostate cancer - the past, present and future.
Marc Carceles-Cordon, Veronica Rodriguez-Bravo, Daniel P Petrylak, Josep Domingo-Domenech
Nature Reviews. Urology. 2026-06-01
Phase 2 study of talabostat, a small molecule inhibitor of dipeptidyl peptidases (DPP), administered in combination with pembrolizumab in patients with small cell neur...
Rahul Aggarwal, Jingsong Zhang, Paul Monk, Xinhua Zhu, Rob Jones
Journal for Immunotherapy of Cancer. 2026-05-11
Correlative Biomarker Analysis of PSMA Expression on CTCs and PSMA Imaging in a Phase I Study of PSMA-Targeted Tubulysin Conjugate EC1169.
Samir Zaidi, Phillip H Kuo, Tiago Paiva Prudente, Kristine P Lacuna, Hani M Babiker
Clinical Cancer Research. 2026-05-01

Journal Articles

Enfortumab Vedotin in Previously Treated Advanced Urothelial Carcinoma
Jonathan E Rosenberg, Daniel P Petrylak, The New England Journal of Medicine
Avelumab Maintenance Therapy for Advanced or Metastatic Urothelial Carcinoma
Cora N Sternberg, Jeanny B Aragon-Ching, Daniel P Petrylak, Petros Grivas, The New England Journal of Medicine

Lectures

EV-201: Results of enfortumab vedotin monotherapy for locally advanced or metastatic urothelial cancer previously treated with platinum and immune checkpoint inhibitors.
2019 ASCO Annual Meeting - 6/1/2019
6th Annual Interdisciplinary Prostate Cancer Congress®
Physicians' Education Resource, LLC , Physicians' Education Resource, LLC, New York, New York - 3/16/2013

Press Mentions

Community Collaboration Supports Prostate Cancer Rally in New HavenJanuary 5th, 2026
Pursuing Bladder Cancer Treatments, Reducing Side EffectsMay 20th, 2025
How Did Biden’s Doctors Miss His Condition?May 19th, 2025